Drugs.com - New Drug Approvals

FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and...

Jun 13, 2025 - 04:20
 0
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and...
Read More

Tags:

Previous Article

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–5...

Next Article

Oil Prices Surge and Stock Markets Stumble After Israel Strikes Iran

Related Posts

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

May 12, 2025  0

FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

FDA Approves Brekiya (dihydroergotamine mesylate) Injec...

May 26, 2025  0

FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to...

May 12, 2025  0